Limertinib Application Scope

Indicated for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation after progression on prior EGFR-TKI therapy, and for first-line treatment of EGFR exon 19 deletion or exon 21 (L858R) mutation-positive NSCLC.

Limertinib Characteristics

Ingredients: Limertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI).
Properties: Irreversibly inhibits EGFR with sensitizing mutations and T790M resistance mutation, with lower activity against wild-type EGFR; has activity against brain metastases.
Packaging Specification: 80 mg/tablet.
Storage: Store as directed on the package; keep away from moisture and heat.
Expiry Date: See package label.
Executive Standard: Not specified in public documents.
Approval Number: Not publicly specified.
Date of Revision: Not specified.
Manufacturer: Co-developed and manufactured by Innovent Biologics and Ask Pharm.

Guidelines for the Use of Aoyixin

Dosage and Administration:
- Recommended Dose:
  - EGFR T790M-positive NSCLC after prior EGFR-TKI therapy: 200 mg once daily orally.
  - First-line EGFR mutation-positive NSCLC: 80 mg twice daily (160 mg total daily dose).
- Administration: Oral, swallow whole with water.
- Missed Dose:
  - Take as soon as remembered
  - skip if close to next scheduled dose.
Adverse Reactions:
- Common Adverse Reactions:
  - Diarrhea
  - rash
  - nausea
  - decreased appetite
  - hypokalemia, anemia
- Serious Adverse Reactions:
  - Severe diarrhea
  - severe rash
  - significant liver function abnormalities
Contraindications: Contraindicated in patients with hypersensitivity to the drug or its components. Use with caution or avoid in pregnancy, breastfeeding, and severe hepatic or renal impairment.
Precautions:
- Confirm EGFR mutation status before initiation.
- Monitor liver function, blood counts, and electrolytes regularly.
- Consider dose reduction or interruption for severe adverse reactions.

Limertinib Interactions

Concomitant use with strong CYP3A4 inhibitors may increase drug exposure; use with CYP3A4 inducers may decrease efficacy.
Safety and interaction data with other EGFR-TKIs are not fully established.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.